{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T04:51:36Z","timestamp":1773723096556,"version":"3.50.1"},"reference-count":24,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The authors of this report present 3 cases of synthetic opioid intoxication complicated by the concomitant presence of the additive xylazine, a nonopioid sedative analgesic and muscle relaxant used in veterinary medicine that potentiates respiratory depression associated with the opioid toxidrome. Three exposed children presented with severe signs and symptoms, 2 of whom experienced cardiac arrest, a need for continuous naloxone infusion or multiple naloxone doses, or mechanical ventilation to treat respiratory failure after their exposures. Additives were detected in urine studies only through the performance of specialized toxicology testing. Detection of xylazine among adult overdose deaths has recently increased sharply, particularly across the northeastern United States. Adulteration by xylazine is an emerging public health threat nationally. Our report reveals that pediatricians should be aware of sentinel drug trends among adults, including the emerging types of illicit, synthetic, or counterfeit formulations of recreational substances, because children may be harmed because of accidental or intentional exposure. Children exposed to dangerous substances also need child protection services that may entail safe relocation outside of the home and the referral of affected caregivers to necessary substance use treatment services. Given epidemic drug use among adults, pediatricians should be competent to recognize common toxidromes and be aware that signs and symptoms may be potentiated by synergistic novel additives or polysubstance exposures. Importantly, standard urine drug screens may not detect synthetic opioid derivatives or contributing additives, so that diagnosis will require specialized toxicology testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2022-058684","type":"journal-article","created":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T03:08:12Z","timestamp":1671764892000},"source":"Crossref","is-referenced-by-count":13,"title":["Xylazine Complicating Opioid Ingestions in Young Children"],"prefix":"10.1542","volume":"151","author":[{"given":"Stephanie Anne","family":"Deutsch","sequence":"first","affiliation":[{"name":"Nemours Children\u2019s Health, Delaware Valley, Department of Pediatrics, Wilmington, Delaware"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan R.","family":"De Jong","sequence":"additional","affiliation":[{"name":"Nemours Children\u2019s Health, Delaware Valley, Department of Pediatrics, Wilmington, Delaware"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2022,12,23]]},"reference":[{"issue":"6408","key":"2023111013534337600_B1","doi-asserted-by":"crossref","first-page":"eaau1184","DOI":"10.1126\/science.aau1184","article-title":"Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016","volume":"361","author":"Jalal","year":"2018","journal-title":"Science"},{"key":"2023111013534337600_B2","unstructured":"National Institute on Drug Abuse\n          . Fentanyl drug facts. Available at: https:\/\/nida.nih.gov\/publications\/drugfacts\/fentanyl. Accessed June 10, 2022"},{"issue":"4","key":"2023111013534337600_B3","doi-asserted-by":"crossref","first-page":"e1009","DOI":"10.1542\/peds.2014-0840","article-title":"Emergency hospitalizations for unsupervised prescription medication ingestions by young children","volume":"134","author":"Lovegrove","year":"2014","journal-title":"Pediatrics"},{"key":"2023111013534337600_B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature","volume":"240","author":"Ruiz-Col\u00f3n","year":"2014","journal-title":"Forensic Sci Int"},{"issue":"2","key":"2023111013534337600_B5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/dta.220","article-title":"Adulterants in illicit drugs: a review of empirical evidence","volume":"3","author":"Cole","year":"2011","journal-title":"Drug Test Anal"},{"issue":"37","key":"2023111013534337600_B6","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.15585\/mmwr.mm7037a4","article-title":"Notes from the field: xylazine detection and involvement in drug overdose deaths \u2013 United States, 2019","volume":"70","author":"Kariisa","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023111013534337600_B7","unstructured":"American College of Emergency Physicians. Tactical Emergency Medicine Section. Xylazine, an emerging adulterant. Available at: https:\/\/www.acep.org\/tacticalem\/newsroom\/oct-2021\/xylazine-an- emerging-adulterant\/. Accessed September 3, 2022"},{"issue":"4","key":"2023111013534337600_B8","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2885.1988.tb00189.x","article-title":"Xylazine--a review of its pharmacology and use in veterinary medicine","volume":"11","author":"Greene","year":"1988","journal-title":"J Vet Pharmacol Ther"},{"key":"2023111013534337600_B9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1747-597X-6-7","article-title":"Xylazine (veterinary sedative) use in Puerto Rico","volume":"6","author":"Torruella","year":"2011","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"3","key":"2023111013534337600_B10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11524-011-9662-6","article-title":"The emerging of xylazine as a new drug of abuse and its health consequences among drug users in Puerto Rico","volume":"89","author":"Reyes","year":"2012","journal-title":"J Urban Health"},{"issue":"3","key":"2023111013534337600_B11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.drugalcdep.2008.03.005","article-title":"GC-MS confirmation of xylazine (Rompun), a veterinary sedative, in exchanged needles","volume":"96","author":"Rodr\u00edguez","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"2023111013534337600_B12","doi-asserted-by":"crossref","first-page":"109380","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"2023111013534337600_B13","doi-asserted-by":"crossref","first-page":"108314","DOI":"10.1016\/j.drugalcdep.2020.108314","article-title":"Steep increases in fentanyl- related mortality west of the Mississippi River: recent evidence from county and state surveillance","volume":"216","author":"Shover","year":"2020","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"2023111013534337600_B14","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/00006565-200112000-00012","article-title":"Severe intoxication from xylazine inhalation","volume":"17","author":"Capraro","year":"2001","journal-title":"Pediatr Emerg Care"},{"issue":"6","key":"2023111013534337600_B15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3109\/15563658108990293","article-title":"Human xylazine overdose: a comparative review with clonidine, phenothiazines, and tricyclic antidepressants","volume":"18","author":"Gallanosa","year":"1981","journal-title":"Clin Toxicol"},{"issue":"4","key":"2023111013534337600_B16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jemermed.2006.02.042","article-title":"Systemic toxicity after an ocular exposure to xylazine hydrochloride","volume":"30","author":"Velez","year":"2006","journal-title":"J Emerg Med"},{"issue":"4","key":"2023111013534337600_B17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/jat\/25.4.245","article-title":"Severe intoxication with the veterinary tranquilizer xylazine in humans","volume":"25","author":"Hoffmann","year":"2001","journal-title":"J Anal Toxicol"},{"issue":"2","key":"2023111013534337600_B18","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2885.1981.tb00715.x","article-title":"The pharmacokinetics of xylazine hydrochloride: an interspecific study","volume":"4","author":"Garcia-Villar","year":"1981","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"2023111013534337600_B19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0379-0738(03)00083-5","article-title":"A reported case involving impaired driving following self-administration of xylazine","volume":"134","author":"Stillwell","year":"2003","journal-title":"Forensic Sci Int"},{"issue":"4","key":"2023111013534337600_B20","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1136\/injuryprev-2020-043968","article-title":"Increasing presence of xylazine in heroin and\/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019","volume":"27","author":"Johnson","year":"2021","journal-title":"Inj Prev"},{"key":"2023111013534337600_B21","unstructured":"American Heart Association\n          . Highlights of the 2020 American Heart Association Guidelines for CPR and ECC. Available at: https:\/\/cpr.heart. org\/-\/media\/cpr-files\/cpr-guidelines- files\/highlights\/hghlghts_2020_ecc_ guidelines_english.pdf. Accessed June 10, 2022"},{"issue":"12","key":"2023111013534337600_B22","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jamapediatrics.2016.2154","article-title":"National trends in hospitalizations for opioid poisonings among children and adolescents, 1997 to 2012","volume":"170","author":"Gaither","year":"2016","journal-title":"JAMA Pediatr"},{"issue":"1","key":"2023111013534337600_B23","doi-asserted-by":"crossref","first-page":"e20173652","DOI":"10.1542\/peds.2017-3652","article-title":"Buprenorphine exposures among children and adolescents reported to US poison control centers","volume":"142","author":"Post","year":"2018","journal-title":"Pediatrics"},{"issue":"1","key":"2023111013534337600_B24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1542\/pir.2019-0309","article-title":"Pediatric ingestions: new high-risk household hazards","volume":"42","author":"Sheridan","year":"2021","journal-title":"Pediatr Rev"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-058684\/1564367\/peds_2022058684.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2022-058684\/1564367\/peds_2022058684.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T13:54:32Z","timestamp":1699624472000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/151\/1\/e2022058684\/190352\/Xylazine-Complicating-Opioid-Ingestions-in-Young"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,23]]},"published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2022-058684","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,23]]},"article-number":"e2022058684"}}